GlassScriptPhysician profile
Stephen Smith Babson
NPI 1699286153
$2,835.85
in general payments reported to CMS, 2019-2025
25 companies · $989 in 2025
The $989 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $548 · 2024: $1,299 · 2025: $989.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,736 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,735.86 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,082.94 | 2023-2025 | Ubrelvy, Qulipta, Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $279.74 | 2023-2025 | Caplyta |
| Lilly USA, LLC | $217.35 | 2023-2025 | Zepbound, Mounjaro, Jardiance |
| Astellas Pharma US INC | $213.69 | 2024-2025 | Veozah |
| Irhythm Technologies, INC. | $121.10 | 2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $98.60 | 2023-2024 | Spravato |
| Madrigal Pharmaceuticals | $83.02 | 2025 | Rezdiffra |
| Supernus Pharmaceuticals, INC. | $75.82 | 2024-2025 | Qelbree |
| Aimmune Therapeutics, INC. | $74.86 | 2024-2025 | Zenpep |
| Exact Sciences Corporation | $63.04 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Pfizer INC. | $56.20 | 2023-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $56.11 | 2023-2024 | |
| Novo Nordisk INC | $47.01 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $46.41 | 2025 | Arexvy, Shingrix, Bexsero |
| Astrazeneca Pharmaceuticals LP | $46.26 | 2025 | Airsupra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $43.64 | 2024 | Apretude |
| Otsuka America Pharmaceutical, INC. | $34.57 | 2024-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $34.22 | 2024-2025 | Camzyos |
| Sanofi-Aventis U.S. LLC | $29.37 | 2025 | |
| Dexcom, INC. | $28.26 | 2023 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $24.90 | 2025 | Fanapt |
| Azurity Pharmaceuticals, INC. | $23.65 | 2023 | Horizant |
| Lundbeck LLC | $19.50 | 2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.17 | 2025 | Xifaxan |
| Biogen, INC. | $17.42 | 2025 | Zurzuvae |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Babson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.